MX2021011688A - Combinaciones utiles en un metodo para tratar sarcoma. - Google Patents
Combinaciones utiles en un metodo para tratar sarcoma.Info
- Publication number
- MX2021011688A MX2021011688A MX2021011688A MX2021011688A MX2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A
- Authority
- MX
- Mexico
- Prior art keywords
- treating sarcoma
- subject
- combinations useful
- sarcoma
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un aspecto descrito en la presente solicitud incluye un método para tratar sarcoma en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva de un compuesto de molécula pequeña. De manera más particular, otro aspecto descrito en la presente solicitud incluye un método para tratar sarcoma en un individuo que lo necesite que comprende, administrar al individuo una cantidad efectiva del compuesto de molécula pequeña descrito en la presente solicitud en combinación con un agente quimioterapéutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962825017P | 2019-03-27 | 2019-03-27 | |
PCT/US2020/025532 WO2020198705A1 (en) | 2019-03-27 | 2020-03-27 | Combinations useful in a method for treating sarcoma |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011688A true MX2021011688A (es) | 2022-01-24 |
Family
ID=72609016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011688A MX2021011688A (es) | 2019-03-27 | 2020-03-27 | Combinaciones utiles en un metodo para tratar sarcoma. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220152024A1 (es) |
EP (1) | EP3947379A4 (es) |
JP (1) | JP2022519930A (es) |
CN (1) | CN114096537A (es) |
AU (1) | AU2020248103A1 (es) |
BR (1) | BR112021019170A2 (es) |
CA (1) | CA3134648A1 (es) |
EA (1) | EA202192349A1 (es) |
IL (1) | IL286647A (es) |
MX (1) | MX2021011688A (es) |
WO (1) | WO2020198705A1 (es) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH593266A5 (es) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
KR20090094148A (ko) * | 2006-12-20 | 2009-09-03 | 제이-씨 헬쓰 케어 리미티드 | 페길화 리포좀 독소루비신의 투여 방법 |
KR102275676B1 (ko) * | 2012-11-21 | 2021-07-12 | 피티씨 테라퓨틱스, 인크. | 치환된 리버스 피리미딘 bmi-1 저해제 |
EP3836932A2 (en) * | 2018-08-17 | 2021-06-23 | PTC Therapeutics, Inc. | Method for treating pancreatic cancer |
SG11202109503TA (en) * | 2019-03-11 | 2021-09-29 | Ptc Therapeutics Inc | Compound form having enhanced bioavailability and formulations thereof |
-
2020
- 2020-03-27 CN CN202080039624.8A patent/CN114096537A/zh active Pending
- 2020-03-27 CA CA3134648A patent/CA3134648A1/en active Pending
- 2020-03-27 WO PCT/US2020/025532 patent/WO2020198705A1/en unknown
- 2020-03-27 MX MX2021011688A patent/MX2021011688A/es unknown
- 2020-03-27 AU AU2020248103A patent/AU2020248103A1/en active Pending
- 2020-03-27 EA EA202192349A patent/EA202192349A1/ru unknown
- 2020-03-27 EP EP20776386.3A patent/EP3947379A4/en active Pending
- 2020-03-27 JP JP2021557396A patent/JP2022519930A/ja active Pending
- 2020-03-27 US US17/441,355 patent/US20220152024A1/en active Pending
- 2020-03-27 BR BR112021019170A patent/BR112021019170A2/pt unknown
-
2021
- 2021-09-23 IL IL286647A patent/IL286647A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL286647A (en) | 2021-10-31 |
EA202192349A1 (ru) | 2022-02-01 |
BR112021019170A2 (pt) | 2022-03-03 |
AU2020248103A1 (en) | 2021-10-21 |
CA3134648A1 (en) | 2020-10-01 |
EP3947379A4 (en) | 2022-12-21 |
JP2022519930A (ja) | 2022-03-25 |
WO2020198705A1 (en) | 2020-10-01 |
EP3947379A1 (en) | 2022-02-09 |
US20220152024A1 (en) | 2022-05-19 |
CN114096537A (zh) | 2022-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
MX2019011431A (es) | Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1). | |
MX2023005160A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma. | |
CL2020003276A1 (es) | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias | |
MX2020010657A (es) | Derivados de oxadiazolina. | |
MY198004A (en) | Antitumoral compounds | |
MX366765B (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple. | |
MX2019010101A (es) | Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
SA521430909B1 (ar) | B تركيبة علف تتضمن مركب سداسي هيدرو حامضى ومركبات وتطبيق منها | |
EA202191631A1 (ru) | Композиции, содержащие бактериальные штаммы | |
WO2021061874A3 (en) | Methods and compositions for treating acute myeloid leukemia | |
NZ733451A (en) | Combination therapy for pulmonary hypertension | |
WO2020055544A3 (en) | Method for treating pancreatic cancer | |
MX2020005707A (es) | Profarmacos de creatina, composiciones y metodos de uso de estos. | |
CL2021001922A1 (es) | Procedimientos para tratamiento de enfermedades con inhibidores de magl. | |
SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
MX2021011688A (es) | Combinaciones utiles en un metodo para tratar sarcoma. | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
PE20200749A1 (es) | Moduladores de la expresion de enac | |
MX2019008535A (es) | Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. | |
MX2021010398A (es) | Metodo para tratar un mieloma multiple. | |
WO2020180842A3 (en) | Aptamers and use thereof | |
GB2543709A (en) | Pharmaceutical agent | |
MX2017005905A (es) | Composicion para extension de cadenas polimericas. | |
MX2021008523A (es) | Metodo para tratar una leucemia mieloide aguda. |